Abstract | OBJECTIVE: METHODS: 50 patients with dilated cardiomyopathy were randomly assigned to double-blind treatment with 2 I.U. of GH or placebo for 3 months. Central hemodynamics were determined by Swan-Ganz catheter and cardiac output was obtained by the thermodilution method. Serum GH and IGF-I levels were measured and systemic NO production was determined from urinary nitrate and cyclic GMP excretion rates in 42 patients. RESULTS: GH treatment caused in comparison to the placebo group a significant increase of IGF-I by 91 ng/ml (P = 0.0001). Urinary excretion rates of nitrate and cyclic GMP increased also significantly by 38 mumol/mmol creatinine (P = 0.027) and 65 nmol/mmol creatinine (P = 0.003), respectively. The parallel increase of both marker molecules indicates increased systemic NO production during GH treatment. CONCLUSION: GH treatment induces a significant, but moderate increase of systemic NO production in patients with dilated cardiomyopathy. This effect may be mediated by IGF-I stimulating endothelial NO synthase.
|
Authors | K J Osterziel, S M Bode-Böger, O Strohm, A E Ellmer, N Bit-Avragim, D Hänlein, M B Ranke, R Dietz, R H Böger |
Journal | Cardiovascular research
(Cardiovasc Res)
Vol. 45
Issue 2
Pg. 447-53
(Jan 14 2000)
ISSN: 0008-6363 [Print] England |
PMID | 10728365
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Nitrates
- Nitric Oxide
- Insulin-Like Growth Factor I
- Growth Hormone
- Cyclic GMP
|
Topics |
- Cardiomyopathy, Dilated
(drug therapy, metabolism)
- Chi-Square Distribution
- Cyclic GMP
(urine)
- Double-Blind Method
- Female
- Growth Hormone
(blood, therapeutic use)
- Humans
- Insulin-Like Growth Factor I
(analysis)
- Male
- Middle Aged
- Nitrates
(urine)
- Nitric Oxide
(physiology)
- Regression Analysis
|